MNLP – Module 7 – Final assessment
Assessment Summary
0 of 20 Questions completed
Questions:
Information
You have already completed the assessment before. Hence you can not start it again.
Assessment is loading…
You must sign in or sign up to start the assessment.
You must first complete the following:
Results
Results
0 of 20 Questions answered correctly
Your time:
Time has elapsed
You have reached 0 of 0 point(s), (0)
Earned Point(s): 0 of 0, (0)
0 Essay(s) Pending (Possible Point(s): 0)
Categories
- Not categorized 0%
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- 12
- 13
- 14
- 15
- 16
- 17
- 18
- 19
- 20
- Current
- Review
- Answered
- Correct
- Incorrect
- Question 1 of 20
1. Question
All new drugs must be tested. Can you match the stage of testing with the rationale?
Sort elements
- Phase II
- Phase IV
- Preclinical
- Phase III
- Phase I
- A. Test for efficacy
- B. Test for pharmacovigilance
- C. Test in cells and animals
- D. Test to compare against existing treatments
- E. Test to determine dose and toxicity
CorrectIncorrect - Question 2 of 20
2. Question
How many of the 5,000 drugs that are developed for the market reach the patient?
CorrectIncorrect - Question 3 of 20
3. Question
In drug development, the term “drug target” means
CorrectIncorrect - Question 4 of 20
4. Question
The process of drug discovery begins with
CorrectIncorrect - Question 5 of 20
5. Question
In pre-clinical testing, the acronym “ADME” stands for
CorrectIncorrect - Question 6 of 20
6. Question
A company developing drugs for a disease will take forward how many drugs from pre-clinical to clinical testing?
CorrectIncorrect - Question 7 of 20
7. Question
Which of the following statements about Phase II clinical trials is not true?
CorrectIncorrect - Question 8 of 20
8. Question
A drug can be submitted for regulatory approval to gain a market licence if the results after which phase of development shows that it is safe and effective
CorrectIncorrect - Question 9 of 20
9. Question
What is the purpose of a health technology assessment?
CorrectIncorrect - Question 10 of 20
10. Question
What type of drug is talquetamab?
CorrectIncorrect - Question 11 of 20
11. Question
Match the drugs with the terms
Sort elements
- Daratumumab
- Mezigdomide
- Belanatamab mafodotin
- Venetoclax
- Monoclonal antibody targeting CD38 on the surface of myeloma cells
- A CELMoD member of the next generation immunomodulatory drug family
- An antibody-drug conjugate that brings a chemotherapy agent in direct contact with cancer cells
- An orally administered pro-survival inhibitor
CorrectIncorrect - Question 12 of 20
12. Question
Natural Killer (NK) cells are from the same family as T and B cells
CorrectIncorrect - Question 13 of 20
13. Question
Type in the words phase, trial, protocol to complete the following sentence.
Every , regardless of , is run according to the
CorrectIncorrect - Question 14 of 20
14. Question
Patients who do not fit the specified eligibility criteria of a trial may still be able to participate if they give their consent.
CorrectIncorrect - Question 15 of 20
15. Question
Assertion: The aim of a Phase IV trial is to further assess the long-term safety and effectiveness of a drug in a wider patient population
BECAUSE
Reason: The European Commission is responsible for granting a new drug European market authorisation
CorrectIncorrect - Question 16 of 20
16. Question
The following are all types of immunotherapy except
CorrectIncorrect - Question 17 of 20
17. Question
How many health technology assessment bodies are there in the UK?
CorrectIncorrect - Question 18 of 20
18. Question
Is the following statement true or false?
Where appropriate, myeloma patients are encouraged to take part in a clinical trial
CorrectIncorrect - Question 19 of 20
19. Question
Despite the introduction and development of newer, more effective treatments myeloma remains an incurable disease
CorrectIncorrect - Question 20 of 20
20. Question
CAR-T cell therapies work by enhancing the ability of B cells to recognise myeloma cells
CorrectIncorrect